Safety and Tolerability of SCH 530348 in Patients Undergoing Non-Urgent Percutaneous Coronary Intervention - TRA-PCI

Description:

The goal of the trial was to evaluate treatment with the platelet thrombin receptor (specifically the PAR-1 receptor) antagonist SCH 530348 compared with placebo in patients undergoing elective percutaneous coronary intervention (PCI).